Verona Pharma plc (NASDAQ: VRNA) Stock Competitors & Peer Comparison
See VRNA's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for VRNA and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| VRTX | $477.10 | -0.95% | 121.1B | 25.35 | $18.82 | N/A |
| REGN | $762.63 | +3.29% | 78.6B | 16.71 | $45.63 | +0.48% |
| ARGX | $853.82 | -3.26% | 54.3B | 78.75 | $11.08 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMDW | $9.57 | -3.14% | 42.7B | -2.32 | -$4.15 | N/A |
| RVMD | $187.53 | -2.41% | 39.9B | -26.52 | -$7.07 | N/A |
| ONC | $316.01 | -1.88% | 33.8B | 70.70 | $4.47 | N/A |
| ALNY | $205.52 | -28.30% | 27.4B | 37.02 | $5.55 | N/A |
| ROIV | $33.91 | -1.77% | 24.5B | -34.86 | -$0.97 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
VRNA vs VRTX Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, VRTX has a market cap of 121.1B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while VRTX trades at $477.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas VRTX's P/E ratio is 25.35. In terms of profitability, VRNA's ROE is -0.02%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, VRNA is less volatile compared to VRTX. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
VRNA vs REGN Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, REGN has a market cap of 78.6B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while REGN trades at $762.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas REGN's P/E ratio is 16.71. In terms of profitability, VRNA's ROE is -0.02%, compared to REGN's ROE of +0.18%. Regarding short-term risk, VRNA is less volatile compared to REGN. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check REGN's competition here
argenx SE (NASDAQ: ARGX)
VRNA vs ARGX Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, ARGX has a market cap of 54.3B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while ARGX trades at $853.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas ARGX's P/E ratio is 78.75. In terms of profitability, VRNA's ROE is -0.02%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, VRNA is less volatile compared to ARGX. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check ARGX's competition here
Seagen Inc. (NASDAQ: SGEN)
VRNA vs SGEN Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas SGEN's P/E ratio is -57.19. In terms of profitability, VRNA's ROE is -0.02%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, VRNA is less volatile compared to SGEN. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check SGEN's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
VRNA vs RVMDW Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, RVMDW has a market cap of 42.7B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while RVMDW trades at $9.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas RVMDW's P/E ratio is -2.32. In terms of profitability, VRNA's ROE is -0.02%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, VRNA is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
VRNA vs RVMD Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, RVMD has a market cap of 39.9B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while RVMD trades at $187.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas RVMD's P/E ratio is -26.52. In terms of profitability, VRNA's ROE is -0.02%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, VRNA is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check RVMD's competition here
BeOne Medicines AG (NASDAQ: ONC)
VRNA vs ONC Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, ONC has a market cap of 33.8B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while ONC trades at $316.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas ONC's P/E ratio is 70.70. In terms of profitability, VRNA's ROE is -0.02%, compared to ONC's ROE of +0.12%. Regarding short-term risk, VRNA is less volatile compared to ONC. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
VRNA vs ALNY Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, ALNY has a market cap of 27.4B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while ALNY trades at $205.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas ALNY's P/E ratio is 37.02. In terms of profitability, VRNA's ROE is -0.02%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, VRNA is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
VRNA vs ROIV Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, ROIV has a market cap of 24.5B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while ROIV trades at $33.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas ROIV's P/E ratio is -34.86. In terms of profitability, VRNA's ROE is -0.02%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, VRNA is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check ROIV's competition here
Incyte Corporation (NASDAQ: INCY)
VRNA vs INCY Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, INCY has a market cap of 24.2B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while INCY trades at $119.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas INCY's P/E ratio is 16.06. In terms of profitability, VRNA's ROE is -0.02%, compared to INCY's ROE of +0.30%. Regarding short-term risk, VRNA is less volatile compared to INCY. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
VRNA vs BNTX Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, BNTX has a market cap of 22.9B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while BNTX trades at $90.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas BNTX's P/E ratio is -19.61. In terms of profitability, VRNA's ROE is -0.02%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, VRNA is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check BNTX's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
VRNA vs UTHR Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, UTHR has a market cap of 22B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while UTHR trades at $517.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas UTHR's P/E ratio is 19.10. In terms of profitability, VRNA's ROE is -0.02%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, VRNA is less volatile compared to UTHR. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check UTHR's competition here
Moderna, Inc. (NASDAQ: MRNA)
VRNA vs MRNA Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, MRNA has a market cap of 21.8B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while MRNA trades at $54.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas MRNA's P/E ratio is -6.73. In terms of profitability, VRNA's ROE is -0.02%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, VRNA is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check MRNA's competition here
Insmed Incorporated (NASDAQ: INSM)
VRNA vs INSM Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, INSM has a market cap of 21.4B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while INSM trades at $98.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas INSM's P/E ratio is -17.15. In terms of profitability, VRNA's ROE is -0.02%, compared to INSM's ROE of -1.30%. Regarding short-term risk, VRNA is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check INSM's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
VRNA vs BGNE Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas BGNE's P/E ratio is -22.55. In terms of profitability, VRNA's ROE is -0.02%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, VRNA is less volatile compared to BGNE. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
VRNA vs DNA-WT Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, VRNA's ROE is -0.02%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, VRNA is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check DNA-WT's competition here
Genmab A/S (NASDAQ: GMAB)
VRNA vs GMAB Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, GMAB has a market cap of 17.7B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while GMAB trades at $28.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas GMAB's P/E ratio is 20.77. In terms of profitability, VRNA's ROE is -0.02%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, VRNA is less volatile compared to GMAB. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check GMAB's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
VRNA vs NBIX Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, NBIX has a market cap of 16.8B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while NBIX trades at $166.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas NBIX's P/E ratio is 24.10. In terms of profitability, VRNA's ROE is -0.02%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, VRNA is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
VRNA vs JAZZ Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, JAZZ has a market cap of 15.9B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while JAZZ trades at $252.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas JAZZ's P/E ratio is 19.66. In terms of profitability, VRNA's ROE is -0.02%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, VRNA is less volatile compared to JAZZ. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
VRNA vs BBIO Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, BBIO has a market cap of 15.7B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while BBIO trades at $80.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas BBIO's P/E ratio is -21.41. In terms of profitability, VRNA's ROE is -0.02%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, VRNA is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check BBIO's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
VRNA vs ASND Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, ASND has a market cap of 15.1B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while ASND trades at $243.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas ASND's P/E ratio is -100.79. In terms of profitability, VRNA's ROE is -0.02%, compared to ASND's ROE of -56.42%. Regarding short-term risk, VRNA is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check ASND's competition here
Exelixis, Inc. (NASDAQ: EXEL)
VRNA vs EXEL Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, EXEL has a market cap of 13.3B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while EXEL trades at $53.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas EXEL's P/E ratio is 15.88. In terms of profitability, VRNA's ROE is -0.02%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, VRNA is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check EXEL's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
VRNA vs KRTX Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas KRTX's P/E ratio is -28.09. In terms of profitability, VRNA's ROE is -0.02%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, VRNA is less volatile compared to KRTX. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check KRTX's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
VRNA vs ARWR Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, ARWR has a market cap of 11.9B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while ARWR trades at $84.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas ARWR's P/E ratio is -39.37. In terms of profitability, VRNA's ROE is -0.02%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, VRNA is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check ARWR's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
VRNA vs BMRN Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, BMRN has a market cap of 11.6B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while BMRN trades at $60.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas BMRN's P/E ratio is 28.86. In terms of profitability, VRNA's ROE is -0.02%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, VRNA is less volatile compared to BMRN. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check BMRN's competition here
Bio-Techne Corporation (NASDAQ: TECH)
VRNA vs TECH Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while TECH trades at $72.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas TECH's P/E ratio is 37.16. In terms of profitability, VRNA's ROE is -0.02%, compared to TECH's ROE of +0.05%. Regarding short-term risk, VRNA is less volatile compared to TECH. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
VRNA vs RNAM Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas RNAM's P/E ratio is -17.39. In terms of profitability, VRNA's ROE is -0.02%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, VRNA is similarly volatile compared to RNAM. This indicates similar risk in terms of short-term price fluctuations for VRNA.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
VRNA vs AXSM Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, AXSM has a market cap of 11.2B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while AXSM trades at $217.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas AXSM's P/E ratio is -56.92. In terms of profitability, VRNA's ROE is -0.02%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, VRNA is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check AXSM's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
VRNA vs MDGL Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, MDGL has a market cap of 10.8B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while MDGL trades at $467.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas MDGL's P/E ratio is -36.51. In terms of profitability, VRNA's ROE is -0.02%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, VRNA is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check MDGL's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
VRNA vs SMMT Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, SMMT has a market cap of 10.1B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while SMMT trades at $13.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas SMMT's P/E ratio is -8.14. In terms of profitability, VRNA's ROE is -0.02%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, VRNA is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check SMMT's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
VRNA vs KRYS Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, KRYS has a market cap of 10.1B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while KRYS trades at $341.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas KRYS's P/E ratio is 45.60. In terms of profitability, VRNA's ROE is -0.02%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, VRNA is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check KRYS's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
VRNA vs HALO Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, HALO has a market cap of 9.8B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while HALO trades at $82.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas HALO's P/E ratio is 17.87. In terms of profitability, VRNA's ROE is -0.02%, compared to HALO's ROE of +1.26%. Regarding short-term risk, VRNA is less volatile compared to HALO. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check HALO's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
VRNA vs CYTK Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, CYTK has a market cap of 9.6B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while CYTK trades at $77.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas CYTK's P/E ratio is -13.23. In terms of profitability, VRNA's ROE is -0.02%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, VRNA is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check CYTK's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
VRNA vs RXDX Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas RXDX's P/E ratio is -56.47. In terms of profitability, VRNA's ROE is -0.02%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, VRNA is less volatile compared to RXDX. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check RXDX's competition here
Abivax S.A. (NASDAQ: ABVX)
VRNA vs ABVX Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, ABVX has a market cap of 9.2B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while ABVX trades at $124.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas ABVX's P/E ratio is -65.48. In terms of profitability, VRNA's ROE is -0.02%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, VRNA is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check ABVX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
VRNA vs NUVL Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas NUVL's P/E ratio is -21.79. In terms of profitability, VRNA's ROE is -0.02%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, VRNA is similarly volatile compared to NUVL. This indicates similar risk in terms of short-term price fluctuations for VRNA.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
VRNA vs CRNX Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, CRNX has a market cap of 8.8B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while CRNX trades at $83.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas CRNX's P/E ratio is -16.28. In terms of profitability, VRNA's ROE is -0.02%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, VRNA is less volatile compared to CRNX. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check CRNX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
VRNA vs PTGX Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, PTGX has a market cap of 8.8B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while PTGX trades at $136.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas PTGX's P/E ratio is -75.49. In terms of profitability, VRNA's ROE is -0.02%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, VRNA is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check PTGX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
VRNA vs IMGN Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas IMGN's P/E ratio is -111.55. In terms of profitability, VRNA's ROE is -0.02%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, VRNA is less volatile compared to IMGN. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check IMGN's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
VRNA vs IONS Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, IONS has a market cap of 8.6B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while IONS trades at $51.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas IONS's P/E ratio is -30.10. In terms of profitability, VRNA's ROE is -0.02%, compared to IONS's ROE of -1.11%. Regarding short-term risk, VRNA is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check IONS's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
VRNA vs PRAX Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, PRAX has a market cap of 8.6B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while PRAX trades at $307.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas PRAX's P/E ratio is -23.02. In terms of profitability, VRNA's ROE is -0.02%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, VRNA is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check PRAX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
VRNA vs SYRE Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, SYRE has a market cap of 8.5B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while SYRE trades at $98.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas SYRE's P/E ratio is -47.27. In terms of profitability, VRNA's ROE is -0.02%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, VRNA is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check SYRE's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
VRNA vs KYMR Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, KYMR has a market cap of 8.5B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while KYMR trades at $103.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas KYMR's P/E ratio is -29.29. In terms of profitability, VRNA's ROE is -0.02%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, VRNA is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check KYMR's competition here
Alkermes plc (NASDAQ: ALKS)
VRNA vs ALKS Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, ALKS has a market cap of 8.4B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while ALKS trades at $48.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas ALKS's P/E ratio is 52.66. In terms of profitability, VRNA's ROE is -0.02%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, VRNA is less volatile compared to ALKS. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check ALKS's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
VRNA vs BPMC Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas BPMC's P/E ratio is -51.58. In terms of profitability, VRNA's ROE is -0.02%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, VRNA is similarly volatile compared to BPMC. This indicates similar risk in terms of short-term price fluctuations for VRNA.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
VRNA vs APGE Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while APGE trades at $134.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas APGE's P/E ratio is -30.97. In terms of profitability, VRNA's ROE is -0.02%, compared to APGE's ROE of -0.33%. Regarding short-term risk, VRNA is less volatile compared to APGE. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check APGE's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
VRNA vs CERE Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas CERE's P/E ratio is -16.47. In terms of profitability, VRNA's ROE is -0.02%, compared to CERE's ROE of -0.72%. Regarding short-term risk, VRNA is less volatile compared to CERE. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check CERE's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
VRNA vs TGTX Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, TGTX has a market cap of 8B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while TGTX trades at $52.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas TGTX's P/E ratio is 17.88. In terms of profitability, VRNA's ROE is -0.02%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, VRNA is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check TGTX's competition here
Immunovant, Inc. (NASDAQ: IMVT)
VRNA vs IMVT Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, IMVT has a market cap of 7.9B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while IMVT trades at $38.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas IMVT's P/E ratio is -14.46. In terms of profitability, VRNA's ROE is -0.02%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, VRNA is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check IMVT's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
VRNA vs PCVX Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, PCVX has a market cap of 7.8B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while PCVX trades at $54.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas PCVX's P/E ratio is -7.86. In terms of profitability, VRNA's ROE is -0.02%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, VRNA is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check PCVX's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
VRNA vs IBRX Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, IBRX has a market cap of 7.5B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while IBRX trades at $7.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas IBRX's P/E ratio is -8.44. In terms of profitability, VRNA's ROE is -0.02%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, VRNA is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check IBRX's competition here
Metsera, Inc. (NASDAQ: MTSR)
VRNA vs MTSR Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas MTSR's P/E ratio is -23.58. In terms of profitability, VRNA's ROE is -0.02%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, VRNA is less volatile compared to MTSR. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check MTSR's competition here
Merus N.V. (NASDAQ: MRUS)
VRNA vs MRUS Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas MRUS's P/E ratio is -17.05. In terms of profitability, VRNA's ROE is -0.02%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, VRNA is similarly volatile compared to MRUS. This indicates similar risk in terms of short-term price fluctuations for VRNA.Check MRUS's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
VRNA vs RYTM Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, RYTM has a market cap of 6.8B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while RYTM trades at $99.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas RYTM's P/E ratio is -31.71. In terms of profitability, VRNA's ROE is -0.02%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, VRNA is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check RYTM's competition here
Arcellx, Inc. (NASDAQ: ACLX)
VRNA vs ACLX Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas ACLX's P/E ratio is -28.27. In terms of profitability, VRNA's ROE is -0.02%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, VRNA is less volatile compared to ACLX. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check ACLX's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
VRNA vs COGT Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, COGT has a market cap of 6.7B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while COGT trades at $38.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas COGT's P/E ratio is -18.45. In terms of profitability, VRNA's ROE is -0.02%, compared to COGT's ROE of -0.83%. Regarding short-term risk, VRNA is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check COGT's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
VRNA vs RETA Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas RETA's P/E ratio is -66.29. In terms of profitability, VRNA's ROE is -0.02%, compared to RETA's ROE of +0.47%. Regarding short-term risk, VRNA is less volatile compared to RETA. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check RETA's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
VRNA vs MIRM Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, MIRM has a market cap of 6.5B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while MIRM trades at $105.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas MIRM's P/E ratio is -7.78. In terms of profitability, VRNA's ROE is -0.02%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, VRNA is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check MIRM's competition here
Belite Bio, Inc (NASDAQ: BLTE)
VRNA vs BLTE Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, BLTE has a market cap of 6.4B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while BLTE trades at $158.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas BLTE's P/E ratio is -84.82. In terms of profitability, VRNA's ROE is -0.02%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, VRNA is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check BLTE's competition here
Erasca, Inc. (NASDAQ: ERAS)
VRNA vs ERAS Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, ERAS has a market cap of 6.3B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while ERAS trades at $18.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas ERAS's P/E ratio is -19.51. In terms of profitability, VRNA's ROE is -0.02%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, VRNA is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check ERAS's competition here
CG Oncology Inc. (NASDAQ: CGON)
VRNA vs CGON Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, CGON has a market cap of 6.3B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while CGON trades at $71.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas CGON's P/E ratio is -30.55. In terms of profitability, VRNA's ROE is -0.02%, compared to CGON's ROE of -0.23%. Regarding short-term risk, VRNA is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check CGON's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
VRNA vs CNTA Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas CNTA's P/E ratio is -22.63. In terms of profitability, VRNA's ROE is -0.02%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, VRNA is similarly volatile compared to CNTA. This indicates similar risk in terms of short-term price fluctuations for VRNA.Check CNTA's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
VRNA vs XENE Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, XENE has a market cap of 6.1B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while XENE trades at $62.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas XENE's P/E ratio is -13.33. In terms of profitability, VRNA's ROE is -0.02%, compared to XENE's ROE of -0.49%. Regarding short-term risk, VRNA is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check XENE's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
VRNA vs LGND Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, LGND has a market cap of 5.8B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while LGND trades at $287.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas LGND's P/E ratio is 34.48. In terms of profitability, VRNA's ROE is -0.02%, compared to LGND's ROE of +0.16%. Regarding short-term risk, VRNA is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check LGND's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
VRNA vs SRRK Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while SRRK trades at $47.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas SRRK's P/E ratio is -13.17. In terms of profitability, VRNA's ROE is -0.02%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, VRNA is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check SRRK's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
VRNA vs PTCT Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, PTCT has a market cap of 5.6B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while PTCT trades at $68.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas PTCT's P/E ratio is -29.19. In terms of profitability, VRNA's ROE is -0.02%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, VRNA is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check PTCT's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
VRNA vs CDTX Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas CDTX's P/E ratio is -19.77. In terms of profitability, VRNA's ROE is -0.02%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, VRNA is similarly volatile compared to CDTX. This indicates similar risk in terms of short-term price fluctuations for VRNA.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
VRNA vs ABCM Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, VRNA's ROE is -0.02%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, VRNA is less volatile compared to ABCM. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
VRNA vs ISEE Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas ISEE's P/E ratio is -22.44. In terms of profitability, VRNA's ROE is -0.02%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, VRNA is less volatile compared to ISEE. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check ISEE's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
VRNA vs APLS Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas APLS's P/E ratio is 38.35. In terms of profitability, VRNA's ROE is -0.02%, compared to APLS's ROE of +0.40%. Regarding short-term risk, VRNA is less volatile compared to APLS. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check APLS's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
VRNA vs TVTX Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, TVTX has a market cap of 5.2B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while TVTX trades at $55.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas TVTX's P/E ratio is -254.05. In terms of profitability, VRNA's ROE is -0.02%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, VRNA is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check TVTX's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
VRNA vs TERN Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas TERN's P/E ratio is -51.41. In terms of profitability, VRNA's ROE is -0.02%, compared to TERN's ROE of -0.20%. Regarding short-term risk, VRNA is less volatile compared to TERN. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check TERN's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
VRNA vs DFTX Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, DFTX has a market cap of 4.7B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while DFTX trades at $43.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas DFTX's P/E ratio is N/A. In terms of profitability, VRNA's ROE is -0.02%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, VRNA is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check DFTX's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
VRNA vs DYN Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, DYN has a market cap of 4.6B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while DYN trades at $25.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas DYN's P/E ratio is -7.82. In terms of profitability, VRNA's ROE is -0.02%, compared to DYN's ROE of -0.64%. Regarding short-term risk, VRNA is less volatile compared to DYN. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check DYN's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
VRNA vs CRSP Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, CRSP has a market cap of 4.6B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while CRSP trades at $47.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas CRSP's P/E ratio is -9.39. In terms of profitability, VRNA's ROE is -0.02%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, VRNA is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check CRSP's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
VRNA vs FOLD Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas FOLD's P/E ratio is -161.00. In terms of profitability, VRNA's ROE is -0.02%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, VRNA is similarly volatile compared to FOLD. This indicates similar risk in terms of short-term price fluctuations for VRNA.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
VRNA vs AKRO Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas AKRO's P/E ratio is -14.57. In terms of profitability, VRNA's ROE is -0.02%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, VRNA is less volatile compared to AKRO. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check AKRO's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
VRNA vs DNTH Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, DNTH has a market cap of 4.5B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while DNTH trades at $106.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas DNTH's P/E ratio is -25.89. In terms of profitability, VRNA's ROE is -0.02%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, VRNA is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check DNTH's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
VRNA vs ALPN Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas ALPN's P/E ratio is -101.52. In terms of profitability, VRNA's ROE is -0.02%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, VRNA is less volatile compared to ALPN. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check ALPN's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
VRNA vs ACAD Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, ACAD has a market cap of 4.4B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while ACAD trades at $25.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas ACAD's P/E ratio is 12.68. In terms of profitability, VRNA's ROE is -0.02%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, VRNA is less volatile compared to ACAD. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check ACAD's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
VRNA vs CAI Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, CAI has a market cap of 4.4B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while CAI trades at $15.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas CAI's P/E ratio is -86.19. In terms of profitability, VRNA's ROE is -0.02%, compared to CAI's ROE of +0.06%. Regarding short-term risk, VRNA is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check CAI's competition here
Veradermics, Incorporated (NYSE: MANE)
VRNA vs MANE Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, MANE has a market cap of 4.4B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while MANE trades at $105.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas MANE's P/E ratio is -33.36. In terms of profitability, VRNA's ROE is -0.02%, compared to MANE's ROE of -0.84%. Regarding short-term risk, VRNA is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check MANE's competition here
Opthea Limited (NASDAQ: OPT)
VRNA vs OPT Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas OPT's P/E ratio is -1.52. In terms of profitability, VRNA's ROE is -0.02%, compared to OPT's ROE of +1.18%. Regarding short-term risk, VRNA is similarly volatile compared to OPT. This indicates similar risk in terms of short-term price fluctuations for VRNA.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
VRNA vs PRTC Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas PRTC's P/E ratio is -3.78. In terms of profitability, VRNA's ROE is -0.02%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, VRNA is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check PRTC's competition here
Celcuity Inc. (NASDAQ: CELC)
VRNA vs CELC Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, CELC has a market cap of 4.2B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while CELC trades at $86.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas CELC's P/E ratio is -22.15. In terms of profitability, VRNA's ROE is -0.02%, compared to CELC's ROE of -2.45%. Regarding short-term risk, VRNA is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check CELC's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
VRNA vs EWTX Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, EWTX has a market cap of 4.1B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while EWTX trades at $38.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas EWTX's P/E ratio is -23.15. In terms of profitability, VRNA's ROE is -0.02%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, VRNA is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check EWTX's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
VRNA vs MRTX Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas MRTX's P/E ratio is -4.82. In terms of profitability, VRNA's ROE is -0.02%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, VRNA is less volatile compared to MRTX. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check MRTX's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
VRNA vs ELVN Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, ELVN has a market cap of 3.9B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while ELVN trades at $54.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas ELVN's P/E ratio is -32.82. In terms of profitability, VRNA's ROE is -0.02%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, VRNA is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check ELVN's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
VRNA vs CPRX Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas CPRX's P/E ratio is 12.30. In terms of profitability, VRNA's ROE is -0.02%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, VRNA is similarly volatile compared to CPRX. This indicates similar risk in terms of short-term price fluctuations for VRNA.Check CPRX's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
VRNA vs RYZB Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas RYZB's P/E ratio is -57.86. In terms of profitability, VRNA's ROE is -0.02%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, VRNA is less volatile compared to RYZB. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
VRNA vs CBAY Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas CBAY's P/E ratio is -32.81. In terms of profitability, VRNA's ROE is -0.02%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, VRNA is less volatile compared to CBAY. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check CBAY's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
VRNA vs VKTX Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while VKTX trades at $31.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas VKTX's P/E ratio is -7.67. In terms of profitability, VRNA's ROE is -0.02%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, VRNA is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check VKTX's competition here
Denali Therapeutics Inc. (NASDAQ: DNLI)
VRNA vs DNLI Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, DNLI has a market cap of 3.7B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while DNLI trades at $23.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas DNLI's P/E ratio is -7.99. In terms of profitability, VRNA's ROE is -0.02%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, VRNA is less volatile compared to DNLI. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check DNLI's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
VRNA vs ORKA Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, ORKA has a market cap of 3.6B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while ORKA trades at $96.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas ORKA's P/E ratio is -49.75. In terms of profitability, VRNA's ROE is -0.02%, compared to ORKA's ROE of -0.26%. Regarding short-term risk, VRNA is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check ORKA's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
VRNA vs ADPT Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, ADPT has a market cap of 3.6B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while ADPT trades at $22.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas ADPT's P/E ratio is -41.80. In terms of profitability, VRNA's ROE is -0.02%, compared to ADPT's ROE of -0.31%. Regarding short-term risk, VRNA is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check ADPT's competition here
Alumis Inc. (NASDAQ: ALMS)
VRNA vs ALMS Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, ALMS has a market cap of 3.6B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while ALMS trades at $28.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas ALMS's P/E ratio is -7.39. In terms of profitability, VRNA's ROE is -0.02%, compared to ALMS's ROE of -0.55%. Regarding short-term risk, VRNA is less volatile compared to ALMS. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check ALMS's competition here
Arcus Biosciences, Inc. (NYSE: RCUS)
VRNA vs RCUS Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, RCUS has a market cap of 3.5B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while RCUS trades at $28.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas RCUS's P/E ratio is -8.66. In terms of profitability, VRNA's ROE is -0.02%, compared to RCUS's ROE of -0.69%. Regarding short-term risk, VRNA is less volatile compared to RCUS. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check RCUS's competition here
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX)
VRNA vs SWTX Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas SWTX's P/E ratio is -13.78. In terms of profitability, VRNA's ROE is -0.02%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, VRNA is similarly volatile compared to SWTX. This indicates similar risk in terms of short-term price fluctuations for VRNA.Check SWTX's competition here
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT)
VRNA vs ARQT Comparison August 2026
Verona Pharma plc (NASDAQ: VRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 72.7B. In comparison, ARQT has a market cap of 3.5B. Regarding current trading prices, VRNA is priced at $106.91 on the NASDAQ, while ARQT trades at $26.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -102.80, whereas ARQT's P/E ratio is -933.00. In terms of profitability, VRNA's ROE is -0.02%, compared to ARQT's ROE of -0.01%. Regarding short-term risk, VRNA is less volatile compared to ARQT. This indicates lower risk in terms of short-term price fluctuations for VRNA.Check ARQT's competition here